Project Grant W81XWH2010861

The National Cancer Institute (NCI) awarded a 5-year, $1,357,965 Project Grant (CFDA 93.396 Cancer Biology Research) to the University of Texas MD Anderson Cancer Center to elucidate the role of T cell ferroptosis and altered 3D chromatin architecture in renal medullary carcinoma (RMC), an aggressive cancer affecting young individuals of African descent, especially those with sickle cell disease (SCD). The key objectives are to: 1) establish the connection between altered chromatin...

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $172,193 to the Dana-Farber Cancer Institute in Boston, MA to conduct research on improving diagnosis and treatment of translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer. The key objectives are to: 1) Develop a method to characterize subtype-specific gene regulatory elements in TRCC by identifying differentially active transcription factors and their...

The National Cancer Institute (CFDA 93.395 Cancer Treatment Research) awarded a $267,298 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research aimed at targeting the CDK4/6 pathway in MIT/TFE-translocation renal cell carcinoma (TRCC), an aggressive and underserved form of kidney cancer. The research project will use genetic and pharmacologic approaches to test the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with PI3K/mTOR pathway...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $546,349 to The University of Texas Southwestern Medical Center to investigate the molecular mechanisms by which the Von Hippel-Lindau (VHL) tumor suppressor regulates gene expression via N6-methyladenosine (m6A) modification in clear cell renal cell carcinoma (ccRCC). The research aims to determine how VHL interacts with the m6A enzymatic complex to control m6A-dependent gene expression,...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $689,914 Project Grant under the Cancer Treatment Research (CFDA 93.395) federal grant program to the Icahn School of Medicine at Mount Sinai. The objective of this 5-year research project is to delineate the mechanisms by which concurrent STK11 and KEAP1 gene mutations in non-small cell lung cancer (NSCLC) promote ferroptosis evasion and therapy resistance, and to establish ferroptosis as a...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This Project Grant award, titled "Exosome Signatures of Kidney Cancer Response to Immune Checkpoint Inhibitor", is funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) for $215,985.00 from April 1, 2025 to March 31, 2027. The award supports a pilot study at Stanford University to investigate whether molecular changes in blood and urine exosomes can serve as early biomarkers to predict patient response to a combination immune checkpoint...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $541,647.00 to The Trustees of the University of Pennsylvania to conduct research on the role of the epigenetic regulator ENL in kidney development and Wilms tumor, the most common kidney cancer in children. The research aims to elucidate the biological functions and mechanisms of ENL and its cancer-associated mutations, with the goal of providing new insights into kidney...

This Project Grant award for $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel, non-invasive urine test for early detection of kidney cancer. The primary objectives are to: Demonstrate the specificity and accuracy of a biomarker for detecting early-stage renal tumors in kidney cancer patients without symptoms. Demonstrate the effectiveness and accuracy of the test for detecting residual...